IBJNews

Lilly sues Hospira over generic version of Gemzar

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.

Hospira is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine. Lilly filed the complaint in federal court in Indianapolis on Tuesday seeking a court order blocking approval, claiming infringement of two patents.

The patent for a method of treating tumors has already been deemed invalid by a federal judge in Detroit. Lilly is appealing that decision. Another Lilly patent ensures a generic version can’t enter the market until November.

Dan Rosenberg, a spokesman for Lake Forest, Ill.-based Hospira, declined to comment on the litigation.

“As a world leader in generic injectable drugs, we remain committed to bringing high quality, lower cost products to market as soon as possible,” Rosenberg said.

Lilly has also sued Novartis AG’s Sandoz unit, Teva Pharmaceutical Industries Ltd. and others to stop a generic version of Gemzar.

ADVERTISEMENT

  • Greed - and not about helping people
    It's possible this drug might just help people, but again BIG drug companies are not honestly about helping people as much as making the almighty $$$

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT